5:59 PM
 | 
Oct 25, 2012
 |  BC Extra  |  Company News

Celgene reports 3Q12 results, cancer data

Celgene Corp. (NASDAQ:CELG) reported 3Q12 results on Thursday along with data for two of its marketed cancer drugs in potentially new indications. Abraxane nab-paclitaxel led to progression-free survival of 4.8 months vs. 2.5 months for dacarbazine (p=0.044) in the Phase III CA033 trial in 529 chemotherapy-naive patients with metastatic melanoma. Additionally, an interim analysis of overall survival showed that Abraxane improved the secondary endpoint vs. dacarbazine, but the difference...

Read the full 335 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >